Equities

Inari Medical Inc

Inari Medical Inc

Actions
  • Price (USD)49.66
  • Today's Change-0.09 / -0.18%
  • Shares traded603.06k
  • 1 Year change-15.93%
  • Beta0.9623
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform6
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Inari Medical Inc have a median target of 66.00, with a high estimate of 86.00 and a low estimate of 48.00. The median estimate represents a 32.66% increase from the last price of 49.75.
High72.9%86.00
Med32.7%66.00
Low-3.5%48.00

Earnings history & estimates in USD

On Oct 28, 2024, Inari Medical Inc reported 3rd quarter 2024 losses of -0.09 per share. This result exceeded the -0.13 consensus loss of the 11 analysts covering the company and under-performed last year's 3rd quarter results by -0.14.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-57.14%
Inari Medical Inc reported annual 2023 losses of -0.03 per share on Feb 28, 2024.
Average growth rate+30.61%
More ▼

Revenue history & estimates in USD

Inari Medical, Inc. had 3rd quarter 2024 revenues of 153.39m. This bettered the 150.67m consensus of the 14 analysts covering the company. This was 32.04% above the prior year's 3rd quarter results.
Average growth rate+4.99%
Inari Medical, Inc. had revenues for the full year 2023 of 493.63m. This was 28.73% above the prior year's results.
Average growth rate+55.16%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.